Thus, the study indicated that circulating PRL can be incorporated into the eye and cleaved to vasoinhibins intraocularly, which could lead to beneficiary outcomes in terms of a vasoinhibin-mediated antagonization of VEGF- and diabetes-induced retinal vasopermeability (Figure 1A; Table 1). Here, VEGFA is linked to diabetes mellitus.